Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of COVAX-19 Vaccine in Healthy Adults
NCT04453852Phase 1Completed
- Sponsor
- Vaxine
- Start
- Jun 2020
- Primary completion
- Feb 2021
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing COVAX-19 Vaccine with Placebo (2 arms). Primary endpoints: Incidence of Adverse Events, COVID19 antibody titers and 1 more. Started Jun 2020; status: completed.
02
Drugs
SpikoGen
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04453852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04453852.